Vimarsana
Biggest News Aggregation in the World

Planned Interim Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Planned Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Planned Interim Analysis Today - Breaking & Trending Today

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023 - Vimarsana News

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Published: June 7, 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,... | June 7, 2023

Source: marketscreener.com
Related Topics:
United StatesAntonio CivitareseKaren PrebleFrederik NevensAlexandre LouvetLynda SzczechNareg SagherianM Michelle BerreyCheng ZouVaclav HejdaResearch DevelopmentGlobenewswire IncCompany On TwitterIntercept Pharmaceuticals IncEuropean Association For The StudyGlobal Corporate CommunicationsInternational Normalized RatioMichelle BerreyChief Medical OfficerPlanned Interim AnalysisActive Controlled Trial EvaluatingObeticholic AcidSerum BiomarkersPrimary BiliaryBezafibrate Fixed Dose
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization - Vimarsana News

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

Published: May 12, 2022

12.05.2022 - -FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Application Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients- -IDMC Unanimously Votes to ...

Source: wallstreet-online.de
Related Topics:
United StatesMitchell SteinerSamuel FischEli LillySexual Health DivisionData Monitoring CommitteeAr Prostate Cancer ProgramCompany To Host Investor Conference CallExchange CommissionCompany FormCorporate CommunicationsBreast Cancer ProgramVeru IncAbemaciclib Combination TherapyMetastatic Breast CancerHost Investor Conference Call TodayQuarter Financial SummaryDate Financial SummaryChief Executive OfficerEmergency UsePipeline HighlightsHigh RiskAcute Respiratory Distress SyndromeStudy Unanimously HaltedIndependent Data Monitoring Committee